Steven P. Treon, M.D., Ph.D

Dr. Steven Treon is the Director of the Bing Center for Waldenström’s Macroglobulinemia and an attending physician for medical oncology, at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group.

After earning a doctorate in tumor immunology from Boston University (BU), Dr Treon did a postgraduate fellowship in the Department of Microbiology at BU School of Medicine. Dr Treon received a medical degree from BU School of Medicine and completed an internship in medicine and a residency in internal medicine at BU Medical Center. Dr Treon also served a clinical fellowship in hematology and oncology at Mass General Hospital and a research fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He received certification from the American Board of Internal Medicine in 1995, and in medical oncology in 1997.

Dr Treon’s main research interests focus on understanding the genetic basis and pathogenesis of Waldenström’s macroglobulinemia and the development of therapeutics for this malignancy. He serves on the editorial boards of the Journal of Clinical Oncology, Blood, Clinical Cancer Research, and The Lancet. Dr Treon is a member of several professional societies including the American Medical Association, American Society of Hematology, American Society of Clinical Oncology, European Society of Hematology and the Massachusetts Medical Society. He has been honored with several research and academic awards from various national and international medical foundations and institutes, including the Robert A. Kyle Award for Waldenström's Macroglobulinemia.

Personal website:

DFCI Profile:

WM Clinical Trials: